申请人:Eisai R&D Management Co., Ltd.
公开号:US08933099B2
公开(公告)日:2015-01-13
The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.
本发明提供了一种具有FGFR抑制活性或其药学上可接受的盐的新化合物,以及含有该化合物的制药组合物。具体而言,本发明提供了以下式(I)所表示的化合物或其药学上可接受的盐:其中n表示0至2;A表示芳基或杂芳基;G表示单键、氧原子或—CH2—;E表示含氮非芳杂环;R1表示烷氧基或类似基团;R2表示氢原子或类似基团;R3表示氢原子、烷基、烷氧基或类似基团,但当E表示氮杂环且R2或R3存在于氮杂环上时,R2或R3不表示氢原子。